← Human Trials & Peer-Reviewed Studies
A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity
Plain-language guide to PMID 32062862 (2020): double-blind randomized controlled trial study of Exenatide.
Key Facts
- PMID
- 32062862
- Journal
- Pediatric obesity
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- Weghuber D et al. (25 authors)
- DOI
- 10.1111/ijpo.12624
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exenatide in this randomized controlled trial publication.
To investigate the effect of exenatide extended release on body mass index (BMI)-SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity.
Why It Was Studied
Glucagon-like-peptide-1 (GLP-1) receptor agonist could be a treatment option for adolescent obesity.
Who Took Part
PubMed indexes the participants as children and teenagers, both men and women.
Six-month, randomized, double-blinded, parallel, placebo-controlled clinical trial in patients (n = 44, 10-18 years, females n = 22) with BMI-SDS > 2.0 or age-adapted-BMI > 30 kg/m2 according to WHO were included.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and parallel-group.
Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Exenatide.
A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.
Groups ran in parallel: each of the participants stayed in one arm throughout.
Oral glucose tolerance tests (OGTT) were conducted at the beginning and end of the intervention.
What Was Measured
PubMed files the paper under topics including Anti-Obesity Agents, Body Mass Index, Exenatide, Glucose Tolerance Test and Pediatric Obesity.
Author keywords: GLP-1 receptor agonist, glucose metabolism, liver steatosis and metabolic syndrome.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exenatide.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2020 (Pediatric obesity), a journal based in England.
More context: the Exenatide compound page, all human trials.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.